Security Snapshot

Kura Oncology, Inc. - Common Stock (KURA) Institutional Ownership

CUSIP: 50127T109

13F Institutional Holders and Ownership History from Q4 2015 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

210

Shares (Excl. Options)

85,248,480

Price

$10.39

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
KURA on Nasdaq
Shares outstanding
87,054,674
Price per share
$8.13
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
85,248,480
Total reported value
$885,585,426
% of total 13F portfolios
0%
Share change
+1,461,857
Value change
+$20,117,899
Number of holders
210
Price from insider filings
$8.13
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Sponsored

Quick Takeaways

  • KURA - Kura Oncology, Inc. - Common Stock is tracked under CUSIP 50127T109.
  • 210 institutions reported positions in Q4 2025.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 210 to 17 between Q4 2025 and Q1 2026.
  • Reported value moved from $885,585,426 to $4,196,115.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 210 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 50127T109?
CUSIP 50127T109 identifies KURA - Kura Oncology, Inc. - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Kura Oncology, Inc. - Common Stock (KURA) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 10% +31% $76,791,609 +$24,465,506 8,677,018 +47% BVF PARTNERS L P/IL 30 Sep 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 9.4% +39% $49,222,110 +$15,381,900 7,561,000 +45% SUVRETTA CAPITAL MANAGEMENT, LLC 31 Mar 2025
BlackRock, Inc. 7.8% -24% $41,202,116 -$10,448,902 6,329,050 -20% BlackRock, Inc. 31 Mar 2025
ARMISTICE CAPITAL, LLC 5.7% +6% $42,597,680 +$2,278,320 4,936,000 +5.7% Armistice Capital, LLC 31 Dec 2025
STATE STREET CORP 5.7% $45,218,095 4,931,090 STATE STREET CORPORATION 31 Dec 2025
EcoR1 Capital, LLC 4.8% $23,520,000 4,200,000 EcoR1 Capital, LLC 30 Jun 2025
RA CAPITAL MANAGEMENT, L.P. 4.9% $26,070,011 4,004,610 RA Capital Management, L.P. 31 Mar 2025

As of 31 Dec 2025, 210 institutional investors reported holding 85,248,480 shares of Kura Oncology, Inc. - Common Stock (KURA). This represents 98% of the company’s total 87,054,674 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Kura Oncology, Inc. - Common Stock (KURA) together control 80% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 10% 9,010,793 -5.3% 0% $93,622,139
BVF INC/IL 9.9% 8,617,162 0% 3% $89,532,313
SUVRETTA CAPITAL MANAGEMENT, LLC 9.9% 8,575,422 +5.7% 2.2% $89,098,635
VANGUARD GROUP INC 6.3% 5,507,627 +0.72% 0% $57,224,245
ARMISTICE CAPITAL, LLC 5.7% 4,936,000 +5.7% 1.3% $51,285,040
STATE STREET CORP 5.7% 4,931,090 +47% 0% $51,234,025
AQR CAPITAL MANAGEMENT LLC 3.5% 3,062,212 +37% 0.02% $31,816,384
Prosight Management, LP 2.9% 2,529,600 -8.3% 5.4% $26,282,544
GEODE CAPITAL MANAGEMENT, LLC 2.3% 2,028,618 -0.94% 0% $21,081,811
JACOBS LEVY EQUITY MANAGEMENT, INC 2.3% 2,022,333 -9.1% 0.08% $21,012,040
GOLDMAN SACHS GROUP INC 2.1% 1,837,264 -30% 0% $19,089,173
RENAISSANCE TECHNOLOGIES LLC 2.1% 1,830,566 +112% 0.03% $19,019,581
MILLENNIUM MANAGEMENT LLC 1.8% 1,584,399 -24% 0.01% $16,461,906
ALETHEA CAPITAL MANAGEMENT, LLC 1.6% 1,422,682 +2.4% 7.2% $14,781,666
MORGAN STANLEY 1.6% 1,389,828 -23% 0% $14,440,320
Qube Research & Technologies Ltd 1.5% 1,333,523 -22% 0.02% $13,855,304
Assenagon Asset Management S.A. 1.3% 1,145,016 -9.5% 0.02% $11,896,716
AMERICAN CENTURY COMPANIES INC 1.3% 1,117,042 +67% 0.01% $11,606,066
DIMENSIONAL FUND ADVISORS LP 1.2% 1,077,818 -5.4% 0% $11,197,203
UBS Group AG 1.2% 1,060,025 +118% 0% $11,013,660
NAN FUNG TRINITY (HK) LTD 1.1% 964,880 +318% 0.79% $10,025,103
ACADIAN ASSET MANAGEMENT LLC 1% 886,579 -16% 0.02% $9,210,000
Rhenman & Partners Asset Management AB 1% 872,000 +78% 0.85% $9,060,080
BANK OF AMERICA CORP /DE/ 0.97% 842,128 +47% 0% $8,749,710
NORTHERN TRUST CORP 0.83% 723,217 -4% 0% $7,514,225

Institutional Holders of Kura Oncology, Inc. - Common Stock (KURA) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 526,716 $4,196,115 -$771,474 $8.13 17
2025 Q4 85,248,480 $885,585,426 +$20,117,899 $10.39 210
2025 Q3 83,884,309 $742,481,432 +$26,729,034 $8.85 197
2025 Q2 82,161,271 $474,076,451 +$3,886,077 $5.77 180
2025 Q1 80,481,583 $531,240,145 -$1,742,391 $6.60 183
2024 Q4 78,800,102 $686,302,860 -$217,671,932 $8.71 184
2024 Q3 82,360,607 $1,606,956,703 +$4,044,498 $19.54 178
2024 Q2 80,489,635 $1,657,260,003 -$4,649,743 $20.59 173
2024 Q1 80,704,151 $1,721,386,349 +$47,334,824 $21.33 162
2023 Q4 78,750,714 $1,132,429,796 +$48,405,539 $14.38 138
2023 Q3 75,320,060 $686,894,075 -$2,210,555 $9.12 131
2023 Q2 75,143,461 $795,074,726 +$20,118,060 $10.58 147
2023 Q1 72,452,228 $885,285,317 +$27,367,401 $12.23 140
2022 Q4 70,164,281 $870,596,716 -$25,367,145 $12.41 139
2022 Q3 71,584,721 $977,803,865 -$10,119,008 $13.66 144
2022 Q2 68,658,415 $1,258,498,156 +$54,233,601 $18.33 142
2022 Q1 65,777,551 $1,057,605,942 +$39,092,796 $16.08 142
2021 Q4 64,108,565 $897,784,334 -$107,625,141 $14.00 143
2021 Q3 66,738,474 $1,250,027,023 -$22,664,956 $18.73 149
2021 Q2 67,619,494 $1,409,907,095 -$33,759,405 $20.85 163
2021 Q1 68,584,982 $1,942,401,972 +$106,818,236 $28.27 162
2020 Q4 65,052,975 $2,124,984,562 +$353,968,960 $32.66 192
2020 Q3 53,818,393 $1,648,931,451 +$50,643,099 $30.64 160
2020 Q2 52,442,231 $855,540,393 +$213,208,168 $16.30 129
2020 Q1 39,802,987 $394,470,751 +$5,045,270 $9.95 113
2019 Q4 38,979,999 $536,059,777 -$17,580,300 $13.75 125
2019 Q3 40,174,979 $609,372,943 +$18,475,235 $15.17 114
2019 Q2 38,684,419 $761,718,678 +$133,021,751 $19.69 121
2019 Q1 32,044,753 $531,121,734 -$3,584,064 $16.59 100
2018 Q4 32,415,330 $454,789,379 -$2,761,213 $14.04 95
2018 Q3 30,235,029 $529,138,565 +$7,587,244 $17.50 112
2018 Q2 29,714,074 $540,689,653 +$112,569,821 $18.20 108
2018 Q1 23,570,284 $441,929,475 +$77,404,250 $18.75 98
2017 Q4 19,535,236 $298,877,651 +$581,471 $15.30 73
2017 Q3 19,416,540 $290,234,810 +$128,771,717 $14.95 64
2017 Q2 10,813,395 $100,551,904 +$4,771,007 $9.30 42
2017 Q1 10,310,503 $90,718,000 +$4,182,413 $8.80 34
2016 Q4 9,877,148 $58,241,000 +$736,496 $5.90 29
2016 Q3 9,748,853 $60,931,000 +$2,850,289 $6.25 25
2016 Q2 9,319,042 $25,248,000 -$3,677,975 $2.71 25
2016 Q1 10,225,954 $41,413,000 -$249,669 $4.05 20
2015 Q4 10,246,869 $86,073,000 +$80,324,000 $8.40 14

Sponsored